Upgrade
2026-01-28
Morgan Stanley
RatingOverweight
FromEqual-Weight
Target$262
From—
JNJ Analyst Ratings
Morgan Stanley upgraded J&J to Overweight on Jan 28, a significant bull signal. Scotiabank initiated at Sector Outperform and Daiwa upgraded to Outperform. Consensus is Buy at $279 average target — Street sees the post-separation JNJ as a cleaner pharma story.
ANALYST RATINGS
JNJBuy$211
Overweight$262
Upgrade
2026-01-28
Sector Outperform$230
Initiated
2025-11-13
Outperform$203
Upgrade
2025-10-20
Overweight$212
Upgrade
2025-10-03
Buy$206
Upgrade
2025-09-23
Initiated
2025-11-13
Scotiabank
RatingSector Outperform
From—
Target$230
From—
Upgrade
2025-10-20
Daiwa Securities
RatingOutperform
FromNeutral
Target$203
From—
Upgrade
2025-10-03
Wells Fargo
RatingOverweight
FromEqual Weight
Target$212
From—
Upgrade
2025-09-23
Guggenheim
RatingBuy
FromNeutral
Target$206
From—
Downgrade
2025-05-13
Leerink Partners
RatingMarket Perform
FromOutperform
Target$153
From—
Resumed
2024-12-10
BofA Securities
RatingNeutral
From—
Target$166
From—
Initiated
2024-11-15
Wolfe Research
RatingOutperform
From—
Target$190
From—
Downgrade
2024-07-23
Daiwa Securities
RatingNeutral
FromOutperform
Target$150
From$160
Resumed
2024-05-30
Goldman
RatingNeutral
From—
Target$160
From—
Upgrade
2024-04-18
HSBC Securities
RatingBuy
FromHold
Target$170
From—
Downgrade
2023-12-13
Wells Fargo
RatingEqual Weight
FromOverweight
Target$163
From$170
Upgrade
2023-12-01
UBS
RatingBuy
FromNeutral
Target$180
From$167
Initiated
2023-10-05
RBC Capital Mkts
RatingOutperform
From—
Target$178
From—
Initiated
2023-09-06
HSBC Securities
RatingHold
From—
Target$175
From—
Resumed
2023-05-30
Citigroup
RatingBuy
From—
Target$185
From—
Initiated
2023-03-29
UBS
RatingNeutral
From—
Target$164
From—
Initiated
2023-03-01
Guggenheim
RatingNeutral
From—
Target$161
From—
Initiated
2022-11-18
Credit Suisse
RatingNeutral
From—
Target$170
From—